## Erik Carl Viktor Holmberg

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/51517/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The wait time to primary surgery in endometrial cancer – impact on survival and predictive factors: a population-based SweGCG study. Acta Oncológica, 2022, 61, 30-37.	0.8	0
2	Base of tongue squamous cell carcinomas, outcome depending on treatment strategy and p16 status. A population-based study from the Swedish Head and Neck Cancer Register. Acta Oncológica, 2022, 61, 433-440.	0.8	1
3	Breast cancer hypoxia in relation to prognosis and benefit from radiotherapy after breast-conserving surgery in a large, randomised trial with long-term follow-up. British Journal of Cancer, 2022, 126, 1145-1156.	2.9	20
4	Tumour-infiltrating lymphocytes add prognostic information for patients with low-risk DCIS: findings from the SweDCIS randomised radiotherapy trial. European Journal of Cancer, 2022, 168, 128-137.	1.3	6
5	C-reactive protein identifies patients at risk of postpancreatectomy hemorrhage. Langenbeck's Archives of Surgery, 2022, 407, 1949-1959.	0.8	1
6	Results from 22 years of Followup in the Göteborg Randomized Population-Based Prostate Cancer Screening Trial. Journal of Urology, 2022, 208, 292-300.	0.2	31
7	Prostate Specific Antigen and Biopsy Contamination in the Göteborg-1 Randomized, Population-Based, Prostate Cancer Screening Trial. Journal of Urology, 2022, 208, 1018-1027.	0.2	4
8	Immune Infiltrate in the Primary Tumor Predicts Effect of Adjuvant Radiotherapy in Breast Cancer; Results from the Randomized SweBCG91RT Trial. Clinical Cancer Research, 2021, 27, 749-758.	3.2	10
9	Evidence for Increased Susceptibility to Breast Cancer From Exposure to Ionizing Radiation Due to a Familial History of Breast Cancer: Results From the Swedish Hemangioma Cohort. American Journal of Epidemiology, 2021, 190, 76-84.	1.6	9
10	Impact of patient, primary tumor and metastatic pattern including tumor location on survival in patients undergoing ablation or resection for colorectal liver metastases: A population-based national cohort study. European Journal of Surgical Oncology, 2021, 47, 375-383.	0.5	17
11	Patient-reported pain after surgical removal of leukoplakia – an observational 1-year follow-up study. Acta Odontologica Scandinavica, 2021, 79, 383-389.	0.9	1
12	Increased risk for renal cell carcinoma in end stage renal disease – a population-based case-control study. Scandinavian Journal of Urology, 2021, 55, 209-214.	0.6	4
13	Clinicopathologic factors associated with malignant transformation of oral leukoplakias: a retrospective cohort study. International Journal of Oral and Maxillofacial Surgery, 2021, 50, 1422-1428.	0.7	14
14	Prognostic and predictive impact of stroma cells defined by PDGFRb expression in early breast cancer: results from the randomized SweBCG91RT trial. Breast Cancer Research and Treatment, 2021, 187, 45-55.	1.1	8
15	Implementation of National Guidelines increased survival in advanced ovarian cancer - A population-based nationwide SweGCG study. Gynecologic Oncology, 2021, 161, 244-250.	0.6	6
16	High PDGFRb Expression Predicts Resistance to Radiotherapy in DCIS within the SweDCIS Randomized Trial. Clinical Cancer Research, 2021, 27, 3469-3477.	3.2	8
17	Lymphoma and multiple myeloma in cohorts of persons exposed to ionising radiation at a young age. Leukemia, 2021, 35, 2906-2916.	3.3	7
18	Preoperative and intraoperative assessment of myometrial invasion in endometrial cancer—A Swedish Gynecologic Cancer Group (SweGCG) study. Acta Obstetricia Et Gynecologica Scandinavica, 2021, 100, 1526-1533.	1.3	16

#	Article	IF	CITATIONS
19	Survival in endometrial cancer in relation to minimally invasive surgery or open surgery – a Swedish Gynecologic Cancer Group (SweGCG) study. BMC Cancer, 2021, 21, 658.	1.1	2
20	Patterns and resectability of colorectal cancer recurrences: outcome study within the COLOFOL trial. BJS Open, 2021, 5, .	0.7	10
21	A national study of healthâ€related quality of life in patients with cancer of the base of the tongue compared to the general population and to patients with tonsillar carcinoma. Head and Neck, 2021, 43, 3843-3856.	0.9	4
22	Survival patterns of invasive lobular and invasive ductal breast cancer in a large population-based cohort with two decades of follow up. Breast, 2021, 59, 294-300.	0.9	12
23	Expression of p53, p63, podoplanin and Ki-67 in recurring versus non-recurring oral leukoplakia. Scientific Reports, 2021, 11, 20781.	1.6	4
24	Prognostic Risk Assessment and Prediction of Radiotherapy Benefit for Women with Ductal Carcinoma In Situ (DCIS) of the Breast, in a Randomized Clinical Trial (SweDCIS). Cancers, 2021, 13, 6103.	1.7	21
25	Is leisure time sitting associated with mortality rates among men diagnosed with localized prostate cancer?. European Journal of Cancer Prevention, 2020, 29, 134-140.	0.6	2
26	Estimates of lung and pancreatic cancer survival in Sweden with and without inclusion of death certificate initiated (DCI) cases. Acta Oncológica, 2020, 59, 1322-1328.	0.8	4
27	Primary treatment and relative survival by stage and age in vulvar squamous cell carcinoma: A population-based SweGCG study. Gynecologic Oncology, 2020, 159, 663-671.	0.6	10
28	Expression of HGF, pMet, and pAkt is related to benefit of radiotherapy after breastâ€conserving surgery: a longâ€ŧerm followâ€up of the SweBCG91â€RT randomised trial. Molecular Oncology, 2020, 14, 2713-2726.	2.1	2
29	Comprehensive Transcriptomic Profiling Identifies Breast Cancer Patients Who May Be Spared Adjuvant Systemic Therapy. Clinical Cancer Research, 2020, 26, 171-182.	3.2	14
30	Return to work after oropharyngeal cancer treatment—Highlighting a growing workingâ€age population. Head and Neck, 2020, 42, 1893-1901.	0.9	13
31	Randomized trial of a left ventricular assist device as destination therapy versus guidelineâ€directed medical therapy in patients with advanced heart failure. Rationale and design of the SWEdish evaluation of left Ventricular Assist Device (SweVAD) trial. European Journal of Heart Failure, 2020, 22, 739-750.	2.9	17
32	Healthâ€related quality of life among tonsillar carcinoma patients in Sweden in relation to treatment and comparison with quality of life among the population. Head and Neck, 2020, 42, 860-872.	0.9	2
33	Influence of primary tumour and patient factors on survival in patients undergoing curative resection and treatment for liver metastases from colorectal cancer. BJS Open, 2020, 4, 118-132.	0.7	15
34	Association of Baseline Prostate-Specific Antigen Level With Long-term Diagnosis of Clinically Significant Prostate Cancer Among Patients Aged 55 to 60 Years. JAMA Network Open, 2020, 3, e1919284.	2.8	33
35	Disease mapping of early- and late-stage cancer to monitor inequalities in early detection: a study of cutaneous malignant melanoma. European Journal of Epidemiology, 2020, 35, 537-547.	2.5	9
36	No Increased Cardiac Mortality or Morbidity of Radiation Therapy in Breast Cancer Patients After Breast-Conserving Surgery: 20-Year Follow-up of the Randomized SweBCGRT Trial. International Journal of Radiation Oncology Biology Physics, 2020, 107, 701-709.	0.4	19

#	Article	IF	CITATIONS
37	Lymphovascular space invasion as a predictive factor for lymph node metastases and survival in endometrioid endometrial cancer – a Swedish Gynecologic Cancer Group (SweGCG) study. Acta Oncológica, 2019, 58, 1628-1633.	0.8	55
38	Distribution of Locoregional Breast Cancer Recurrence in Relation to Postoperative Radiation Fields and Biological Subtypes. International Journal of Radiation Oncology Biology Physics, 2019, 105, 285-295.	0.4	15
39	Clinicogenomic Radiotherapy Classifier Predicting the Need for Intensified Locoregional Treatment After Breast-Conserving Surgery for Early-Stage Breast Cancer. Journal of Clinical Oncology, 2019, 37, 3340-3349.	0.8	61
40	Primary treatment patterns and survival of cervical cancer in Sweden: A population-based Swedish Gynecologic Cancer Group Study. Gynecologic Oncology, 2019, 155, 229-236.	0.6	12
41	Early mortality after diagnosis of cancer of the head and neck – A population-based nationwide study. PLoS ONE, 2019, 14, e0223154.	1.1	19
42	Abnormal cervical cytology is associated with preterm delivery: A population based study. Acta Obstetricia Et Gynecologica Scandinavica, 2019, 98, 777-786.	1.3	8
43	The impact of increased immigration to Sweden on the incidence and treatment of patients with HCC and underlying liver disease. Scandinavian Journal of Gastroenterology, 2019, 54, 746-752.	0.6	5
44	DNA ploidy status, S-phase fraction, and p53 are not independent prognostic factors for survival in endometrioid endometrial carcinoma FIGO stage l–III. International Journal of Gynecological Cancer, 2019, 29, 305-311.	1.2	1
45	Sociodemographic disparities in stage-specific incidences of endometrial cancer: a registry-based study in West Sweden, 1995–2016. Acta Oncológica, 2019, 58, 845-851.	0.8	19
46	Combined Testing of p16 Tumour-suppressor Protein and Human Papillomavirus in Patients With Oral Leukoplakia and Oral Squamous Cell Carcinoma. Anticancer Research, 2019, 39, 1293-1300.	0.5	13
47	The Value of an Extensive Transrectal Repeat Biopsy with Anterior Sampling in Men on Active Surveillance for Low-risk Prostate Cancer: A Comparison from the Randomised Study of Active Monitoring in Sweden (SAMS). European Urology, 2019, 76, 461-466.	0.9	10
48	Radiationâ€induced genomic instability in breast carcinomas of the Swedish hemangioma cohort. Genes Chromosomes and Cancer, 2019, 58, 627-635.	1.5	6
49	Rational targeting of population groups and residential areas for colorectal cancer screening. Cancer Epidemiology, 2019, 60, 23-30.	0.8	10
50	Effect of Radiotherapy After Breast-Conserving Surgery Depending on the Presence of Tumor-Infiltrating Lymphocytes: A Long-Term Follow-Up of the SweBCG91RT Randomized Trial. Journal of Clinical Oncology, 2019, 37, 1179-1187.	0.8	41
51	Recurrence rates after surgical removal of oral leukoplakia—A prospective longitudinal multi-centre study. PLoS ONE, 2019, 14, e0225682.	1.1	34
52	Increased Overall Mortality Even after Risk Reducing Surgery for BRCA-Positive Women in Western Sweden. Genes, 2019, 10, 1046.	1.0	3
53	Breast cancer survival trends in different stages and age groups – a population-based study 1989–2013. Acta Oncológica, 2019, 58, 45-51.	0.8	22

4

#	Article	IF	CITATIONS
55	Title is missing!. , 2019, 14, e0225682.		0
56	Title is missing!. , 2019, 14, e0225682.		0
57	Title is missing!. , 2019, 14, e0225682.		0
58	Title is missing!. , 2019, 14, e0223154.		0
59	Title is missing!. , 2019, 14, e0223154.		0
60	Title is missing!. , 2019, 14, e0223154.		0
61	Title is missing!. , 2019, 14, e0223154.		0
62	Lenalidomide versus lenalidomideÂ+Âdexamethasone prolonged treatment after secondâ€line lenalidomideÂ+Âdexamethasone induction in multiple myeloma. Cancer Medicine, 2018, 7, 2256-2268.	1.3	1
63	Renal function and outcome after heart transplantation. Journal of Thoracic and Cardiovascular Surgery, 2018, 155, 1593-1604.e1.	0.4	58
64	Eighteen-year follow-up of the Göteborg Randomized Population-based Prostate Cancer Screening Trial: effect of sociodemographic variables on participation, prostate cancer incidence and mortality. Scandinavian Journal of Urology, 2018, 52, 27-37.	0.6	53
65	Lymph node metastases as only qualifier for stage IV serous ovarian cancer confers longer survival than other sites of distant disease – a Swedish Gynecologic Cancer Group (SweGCG) study. Acta Oncológica, 2018, 57, 331-337.	0.8	17
66	Data quality in the Swedish Quality Register of Gynecologic Cancer – a Swedish Gynecologic Cancer Group (SweGCG) study. Acta Oncológica, 2018, 57, 346-353.	0.8	41
67	COX-2 expression and effects of celecoxib in addition to standard chemotherapy in advanced non-small cell lung cancer. Acta Oncológica, 2018, 57, 244-250.	0.8	20
68	Degree of differentiation of cutaneous squamous cell carcinoma: a comparison between a Swedish cohort of organ transplant recipients and immunocompetent patients. Dermatology Practical and Conceptual, 2018, 8, 330-336.	0.5	6
69	Addition of alfa fetoprotein to traditional criteria for hepatocellular carcinoma improves selection accuracy in liver transplantation. Scandinavian Journal of Gastroenterology, 2018, 53, 976-983.	0.6	4
70	Dose escalation to 84 Gy with concurrent chemotherapy in stage III NSCLC appears excessively toxic: Results from a prematurely terminated randomized phase II trial. Lung Cancer, 2018, 122, 180-186.	0.9	14
71	Gallbladder cancer – no improvement in survival over time in a Swedish population. Acta Oncológica, 2018, 57, 1482-1489.	0.8	15
72	Leukaemia and myeloid malignancy among people exposed to low doses (<100 mSv) of ionising radiation during childhood: a pooled analysis of nine historical cohort studies. Lancet Haematology,the, 2018, 5, e346-e358.	2.2	103

#	Article	IF	CITATIONS
73	Comprehensive transcriptomic profiling to identify breast cancer patients that may be spared adjuvant systemic therapy Journal of Clinical Oncology, 2018, 36, 535-535.	0.8	1
74	Continuous improvement in outcome after heart transplantation — Long-term follow-up after three decades of experience. International Journal of Cardiology, 2017, 231, 188-194.	0.8	15
75	Thyroid Cancer Following Childhood Low-Dose Radiation Exposure: A Pooled Analysis of Nine Cohorts. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 2575-2583.	1.8	112
76	Populationâ€based cohort study of the effect of endometrial cancer classification and treatment criteria on longâ€term survival. International Journal of Gynecology and Obstetrics, 2017, 138, 183-189.	1.0	4
77	Risk factors for lymph node metastases in women with endometrial cancer: A populationâ€based, nationâ€wide register study—On behalf of the Swedish Gynecological Cancer Group. International Journal of Cancer, 2017, 140, 2693-2700.	2.3	23
78	Results of preoperative chemoradiotherapy for patients with advanced cancer of the nasal cavity and paranasal sinuses. Acta Oto-Laryngologica, 2017, 137, 1292-1300.	0.3	16
79	Population-based study of survival for women with serous cancer of the ovary, fallopian tube, peritoneum or undesignated origin - on behalf of the Swedish gynecological cancer group (SweGCG). Gynecologic Oncology, 2017, 144, 167-173.	0.6	23
80	Response to Radiotherapy After Breast-Conserving Surgery in Different Breast Cancer Subtypes in the Swedish Breast Cancer Group 91 Radiotherapy Randomized Clinical Trial. Journal of Clinical Oncology, 2017, 35, 3222-3229.	0.8	74
81	Staging and therapy for patients with hepatocellular cancer in a defined population from 2000 to 2011 – active palliative treatment improved overall survival. Acta Oncológica, 2016, 55, 297-302.	0.8	1
82	Acute de novo Leukemia in Estonia and Western Sweden 1982-2006: Positive Trend in the Survival of Acute Leukemia over 25 Years. Acta Haematologica, 2016, 136, 167-173.	0.7	2
83	Thyroid Cancer after Childhood Exposure to External Radiation: An Updated Pooled Analysis of 12 Studies. Radiation Research, 2016, 185, 473.	0.7	124
84	Long-term Results of Active Surveillance in the Göteborg Randomized, Population-based Prostate Cancer Screening Trial. European Urology, 2016, 70, 760-766.	0.9	130
85	No breast cancer subgroup can be spared postoperative radiotherapy after breast-conserving surgery. Fifteen-year results from the Swedish Breast Cancer Group randomised trial, SweBCG 91 RT. European Journal of Cancer, 2016, 67, 57-65.	1.3	50
86	SPACE – A randomized study of SBRT vs conventional fractionated radiotherapy in medically inoperable stage I NSCLC. Radiotherapy and Oncology, 2016, 121, 1-8.	0.3	270
87	Centralized primary care of advanced ovarian cancer improves complete cytoreduction and survival - A population-based cohort study. Gynecologic Oncology, 2016, 142, 211-216.	0.6	69
88	Acute Myeloid Leukemia in Adolescents and Young Adults Treated in Pediatric and Adult Departments in the Nordic Countries. Pediatric Blood and Cancer, 2016, 63, 83-92.	0.8	16
89	The Effect of Start and Stop Age at Screening on the Risk of Being Diagnosed with Prostate Cancer. Journal of Urology, 2016, 195, 1390-1396.	0.2	20
90	Cutaneous malignant melanoma show geographic and socioeconomic disparities in stage at diagnosis and excess mortality. Acta Oncológica, 2016, 55, 993-1000.	0.8	23

#	Article	IF	CITATIONS
91	Measured and not estimated glomerular filtration rate should be used to assess renal function in heart transplant recipients. Nephrology Dialysis Transplantation, 2016, 31, 1182-1189.	0.4	26
92	The roles of stress and social support in prostate cancer mortality. Scandinavian Journal of Urology, 2016, 50, 47-55.	0.6	16
93	Proteasome inhibitors and <scp>IM</scp> iDs can overcome some highâ€risk cytogenetics in multiple myeloma but not gain 1q21. European Journal of Haematology, 2016, 96, 46-54.	1.1	35
94	Radiation Therapy to the Plexus Brachialis inÂBreast Cancer Patients: Analysis of Paresthesia in Relation to Dose and Volume. International Journal of Radiation Oncology Biology Physics, 2015, 92, 277-283.	0.4	16
95	Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients. Haematologica, 2015, 100, 107-113.	1.7	356
96	Opportunistic Testing Versus Organized Prostate-specific Antigen Screening: Outcome After 18 Years in the GA¶teborg Randomized Population-based Prostate Cancer Screening Trial. European Urology, 2015, 68, 354-360.	0.9	110
97	Breast cancer risk and possible mechanisms of radiation-induced genomic instability in the Swedish hemangioma cohort after reanalyzed dosimetry. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2015, 775, 1-9.	0.4	33
98	Oral and lip cancer in solid organ transplant patients – A cohort study from a Swedish Transplant Centre. Oral Oncology, 2015, 51, 146-150.	0.8	25
99	No clear effect of postoperative radiotherapy on survival of breast cancer patients with one to three positive nodes: a population-based study. Annals of Oncology, 2015, 26, 1149-1154.	0.6	30
100	Support for downâ€staging of pregnancyâ€associated cervical cancer. Acta Obstetricia Et Gynecologica Scandinavica, 2015, 94, 654-659.	1.3	10
101	Increased incidence of another cancer in myeloproliferative neoplasms patients at the time of diagnosis. European Journal of Haematology, 2015, 94, 152-156.	1.1	32
102	Physical Activity and Survival among Men Diagnosed with Prostate Cancer. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 57-64.	1.1	115
103	Radical prostatectomy versus high-dose irradiation in localized/locally advanced prostate cancer: A Swedish multicenter randomized trial with patient-reported outcomes. Acta Oncológica, 2015, 54, 875-881.	0.8	50
104	A population-based study of pelvic serous carcinoma in Sweden: Primary site, FIGO stage and survival Journal of Clinical Oncology, 2015, 33, e16533-e16533.	0.8	0
105	No clinically relevant effect on cognitive outcomes after low-dose radiation to the infant brain: A population-based cohort study in Sweden. Acta Oncológica, 2014, 53, 1143-1150.	0.8	18
106	Addition of thalidomide to melphalan and prednisone treatment prolongs survival in multiple myeloma – a retrospective population based study of 1162 patients. European Journal of Haematology, 2014, 92, 19-25.	1.1	4
107	ONLINE REPORT IN REAL TIME FROM THE NATIONAL PROSTATE CANCER REGISTER (NPCR) OF SWEDEN, A NEW AND EFFICIENT TOOL FOR QUALITY ASSURANCE. BMJ Quality and Safety, 2014, 23, 349.1-349.	1.8	0
108	The incidence rate of pituitary adenomas in western Sweden for the period 2001–2011. European Journal of Endocrinology, 2014, 171, 519-526.	1.9	226

#	Article	IF	CITATIONS
109	Rehospitalization after Radical Prostatectomy in a Nationwide, Population Based Study. Journal of Urology, 2014, 192, 112-119.	0.2	25
110	Body mass index and weight change in men with prostate cancer: progression and mortality. Cancer Causes and Control, 2014, 25, 933-943.	0.8	48
111	Tricuspid regurgitation influences outcome after heart transplantation. Journal of Heart and Lung Transplantation, 2014, 33, 829-835.	0.3	21
112	The Use of Novel Drugs Can Effectively Improve Response, Delay Relapse and Enhance Overall Survival in Multiple Myeloma Patients with Renal Impairment. PLoS ONE, 2014, 9, e101819.	1.1	49
113	The Study of Active Monitoring in Sweden (SAMS): A randomized study comparing two different follow-up schedules for active surveillance of low-risk prostate cancer. Scandinavian Journal of Urology, 2013, 47, 347-355.	0.6	25
114	Outcome Following Active Surveillance of Men with Screen-detected Prostate Cancer. Results from the Göteborg Randomised Population-based Prostate Cancer Screening Trial. European Urology, 2013, 63, 101-107.	0.9	154
115	Risk of localized and advanced prostate cancer among immigrants versus native-born Swedish men: a nation-wide population-based study. Cancer Causes and Control, 2013, 24, 383-390.	0.8	10
116	Incidence of Prostate Cancer After Termination of Screening in a Population-based Randomised Screening Trial. European Urology, 2013, 64, 703-709.	0.9	33
117	Differences in survival from prostate cancer in Denmark, Iceland and Sweden. European Journal of Cancer, 2013, 49, 1984-1992.	1.3	13
118	Sequential population-based studies over 25Âyears on the incidence and survival of acute de novo leukemias in Estonia and in a well-defined region of western Sweden during 1982–2006: a survey of patients aged ≥65Âyears. Medical Oncology, 2013, 30, 487.	1.2	1
119	A population-based study of tumours of the renal pelvis and ureter: Incidence, aetiology and histopathological findings. Scandinavian Journal of Urology, 2013, 47, 491-496.	0.6	5
120	Kidney cancer in Sweden: A decrease in incidence and tumour stage, 1979 – 2001. Scandinavian Journal of Urology, 2013, 47, 302-310.	0.6	9
121	Long-term follow-up after radical cystectomy with emphasis on complications and reoperations: A Swedish population-based survey. Scandinavian Journal of Urology and Nephrology, 2012, 46, 14-18.	1.4	19
122	Efficacy versus effectiveness study design within the European screening trial for prostate cancer: consequences for cancer incidence, overall mortality and cancer-specific mortality. Journal of Medical Screening, 2012, 19, 133-140.	1.1	7
123	A Pooled Analysis of Thyroid Cancer Incidence Following Radiotherapy for Childhood Cancer. Radiation Research, 2012, 178, 365.	0.7	93
124	Mutated KRAS Is an Independent Negative Prognostic Factor for Survival in NSCLC Stage III Disease Treated with High-Dose Radiotherapy. Lung Cancer International, 2012, 2012, 1-6.	1.2	12
125	Risk Factors of Developing Long-Lasting Breast Pain After Breast Cancer Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2012, 83, 71-78.	0.4	41
126	337 READMISSION AFTER RADICAL PROSTATECTOMY. NATION-WIDE, POPULATION-BASED STUDY IN PCBASE SWEDEN. Journal of Urology, 2012, 187, .	0.2	0

#	Article	IF	CITATIONS
127	Long-term symptoms after radiotherapy of supraclavicular lymph nodes in breast cancer patients. Radiotherapy and Oncology, 2012, 103, 155-160.	0.3	35
128	Prostate cancer risk variants are not associated with disease progression. Prostate, 2012, 72, 30-39.	1.2	15
129	Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study. European Journal of Haematology, 2012, 88, 485-496.	1.1	42
130	Concurrent cetuximab and radiotherapy after docetaxel–cisplatin induction chemotherapy in stage III NSCLC: Satellite—A phase II study from the Swedish Lung Cancer Study Group. Lung Cancer, 2011, 71, 166-172.	0.9	51
131	Effect of celecoxib on survival in patients with advanced non-small cell lung cancer: A double blind randomised clinical phase III trial (CYCLUS study) by the Swedish Lung Cancer Study Group. European Journal of Cancer, 2011, 47, 1546-1555.	1.3	59
132	No excess mortality after prostate biopsy: results from the European Randomized Study of Screening for Prostate Cancer. BJU International, 2011, 107, 1912-1917.	1.3	29
133	Melphalan 100 mg/m2 with stem cell support as first relapse treatment is safe and effective for myeloma patients with long remission after autologous stem cell transplantation. European Journal of Haematology, 2011, 87, 117-122.	1.1	15
134	The Incidence and Survival of Acute de novo Leukemias in Estonia and in a Well-Defined Region of Western Sweden during 1997–2001: A Survey of Patients Aged 16–64 Years. Acta Haematologica, 2011, 126, 176-185.	0.7	3
135	Breast cancer risk after radiation treatment at infancy: potential consequences of radiation-induced genomic instability. Radiation Protection Dosimetry, 2011, 143, 375-379.	0.4	9
136	High accuracy of Swedish death certificates in men participating in screening for prostate cancer: A comparative study of official death certificates with a cause of death committee using a standardized algorithm. Scandinavian Journal of Urology and Nephrology, 2011, 45, 226-232.	1.4	46
137	Cancer incidence in a petrochemical industry area in Sweden. Science of the Total Environment, 2010, 408, 4482-4487.	3.9	43
138	Rectal washout and local recurrence of cancer after anterior resection. British Journal of Surgery, 2010, 97, 1589-1597.	0.1	44
139	The incidence and survival of acute de novo leukemias in Estonia and in a well-defined region of western Sweden during 1997–2001: A survey of patients aged ≥65 years. Cancer Epidemiology, 2010, 34, 24-28.	0.8	3
140	Regional differences in local recurrence rates after rectal cancer surgery. Colorectal Disease, 2010, 12, e206-15.	0.7	9
141	Outcomes in Localized Prostate Cancer: National Prostate Cancer Register of Sweden Follow-up Study. Journal of the National Cancer Institute, 2010, 102, 950-958.	3.0	211
142	Outcome of Primary Versus Deferred Radical Prostatectomy in the National Prostate Cancer Register of Sweden Follow-Up Study. Journal of Urology, 2010, 184, 1322-1327.	0.2	48
143	Symptoms 10–17 years after breast cancer radiotherapy data from the randomised SWEBCG91-RT trial. Radiotherapy and Oncology, 2010, 97, 281-287.	0.3	38
144	Mortality results from the Göteborg randomised population-based prostate-cancer screening trial. Lancet Oncology, The, 2010, 11, 725-732.	5.1	843

#	Article	IF	CITATIONS
145	Variation in position and volume of organs at risk in the small pelvis. Acta Oncológica, 2010, 49, 491-499.	0.8	13
146	Abstract P4-10-03: Long-Term Follow-Up of SweBCG 91RT, a Randomized Trial of Breast Conservation Surgery with and without Radiotherapy from the Swedish Breast Cancer Group. , 2010, , .		0
147	Nationwide population-based study on 30-day mortality after radical prostatectomy in Sweden. Scandinavian Journal of Urology and Nephrology, 2009, 43, 350-356.	1.4	16
148	Breast cancer risk among Swedish hemangioma patients and possible consequences of radiation-induced genomic instability. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2009, 669, 48-55.	0.4	20
149	Leukaemia incidence in people living close to an oil refinery. Environmental Research, 2009, 109, 985-990.	3.7	33
150	SURVEILLANCE, RADICAL PROSTATECTOMY, OR RADIOTHERAPY FOR PROSTATE CANCER: POPULATION-BASED, NATION-WIDE COHORT STUDY ON IN THE NATIONAL PROSTATE CANCER REGISTER (NPCR). Journal of Urology, 2009, 181, 59-59.	0.2	1
151	A Population-Based 5-Year Cohort Study Including All Cases of Epithelial Ovarian Cancer in Western Sweden: 10-Year Survival and Prognostic Factors. International Journal of Gynecological Cancer, 2009, 19, 116-123.	1.2	43
152	Cyclophosphamide plus dexamethasone is an efficient initial treatment before high-dose melphalan and autologous stem cell transplantation in patients with newly diagnosed multiple myeloma. Cancer, 2008, 112, 129-135.	2.0	40
153	Surveillance and Deferred Treatment for Localized Prostate Cancer. Population Based Study in the National Prostate Cancer Register of Sweden. Journal of Urology, 2008, 180, 2423-2430.	0.2	30
154	Completeness and correctness of registration of renal pelvic and ureteral cancer in the Swedish Cancer Registry. Scandinavian Journal of Urology and Nephrology, 2008, 42, 12-17.	1.4	38
155	Clinical characteristics and primary treatment of prostate cancer in Sweden between 1996 and 2005. Scandinavian Journal of Urology and Nephrology, 2007, 41, 456-477.	1.4	98
156	Altered transforming growth factor-β pathway expression pattern in rat endometrial cancer. Cancer Genetics and Cytogenetics, 2007, 177, 43-50.	1.0	5
157	Attitude towards remission induction for elderly patients with acute myeloid leukemia influences survival. Leukemia, 2006, 20, 42-47.	3.3	91
158	Dexamethasone and Cyclophosphamide: More Convenient and as Effective as VAD before High-Dose Melphalan and Autologous Transplantation in Newly Diagnosed Multiple Myeloma. Results of a Randomized NMSG Trial Blood, 2006, 108, 793-793.	0.6	0
159	Improved survival with clinical guidelines? Evaluation of a quality register linked to clinical guidelines for ovarian cancer in the western health care region in Sweden between 1 September 1993 and 1 June 1998. Acta Obstetricia Et Gynecologica Scandinavica, 2005, 84, 1113-1118.	1.3	12
160	The impact of reproductive factors on breast cancer risk - The feasibility of using Swedish population-based registers to account for the effect of confounding in cohort studies. Cancer Causes and Control, 2005, 16, 235-243.	0.8	7
161	The Incidence and Survival of AcuteDe NovoLeukaemias in Estonia and in a Well Defined Region of Western Sweden During 1982 – 1996: A Survey of Patients Aged 16 – 64 Years. Leukemia and L 2004, 45, 915-921.	.y <b>mp</b> homa	, 7
162	The incidence and survival of acute de novo leukaemias in Estonia and in a well-defined region of western Sweden during 1982-1996: a survey of patients aged >=65 years. Journal of Internal Medicine, 2004, 256, 79-85.	2.7	7

#	Article	IF	CITATIONS
163	Cancer and oral lichen planus in a Swedish population. Oral Oncology, 2004, 40, 131-138.	0.8	90
164	Breast conservation surgery, with and without radiotherapy, in women with lymph node-negative breast cancer: a randomised clinical trial in a population with access to public mammography screening. European Journal of Cancer, 2003, 39, 1690-1697.	1.3	148
165	Radiation Effects on Breast Cancer Risk: A Pooled Analysis of Eight Cohorts. Radiation Research, 2002, 158, 220-235.	0.7	474
166	Dose–Response Relationship for Parathyroid Adenoma after Exposure to Ionizing Radiation in Infancy. Radiation Research, 2002, 158, 418-423.	0.7	20
167	Excess breast cancer risk and the role of parity, age at first childbirth and exposure to radiation in	2.9	39
168	Prospective Registration of all Patients in a Geographical Region with Newly Diagnosed Bladder Carcinomas during a Two-year Period. Scandinavian Journal of Urology and Nephrology, 2000, 34, 95-101.	1.4	25
169	Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Nordic Myeloma Study Group. Blood, 2000, 95, 7-11.	0.6	261
170	Serum Hyaluronan in Patients With Multiple Myeloma: Correlation With Survival and Ig Concentration. Blood, 1999, 93, 4144-4148.	0.6	36
171	Prognostic evaluation in multiple myeloma: an analysis of the impact of new prognostic factors. British Journal of Haematology, 1999, 106, 1005-1012.	1.2	53
172	RECURRENCE AND PROGRESSION IN LOW GRADE PAPILLARY UROTHELIAL TUMORS. Journal of Urology, 1999, 162, 702-707.	0.2	171
173	Breast Cancer Risk after Radiotherapy in Infancy: A Pooled Analysis of Two Swedish Cohorts of 17,202 Infants. Radiation Research, 1999, 151, 626.	0.7	64
174	Survival in conventionally treated younger (<60 years) multiple myeloma patients: no improvement during two decades. European Journal of Haematology, 1999, 62, 271-272.	1.1	26
175	Breast cancer risk after radiotherapy in infancy: a pooled analysis of two Swedish cohorts of 17,202 infants. Radiation Research, 1999, 151, 626-32.	0.7	21
176	Prognostic value of bone marrow biopsy in operable breast cancer patients at the time of initial diagnosis: Results of a 20-year median follow-up. Breast Cancer Research and Treatment, 1998, 49, 27-33.	1.1	91
177	Soft tissue sarcoma after treatment for breast cancer—A Swedish population-based study. European Journal of Cancer, 1998, 34, 2068-2075.	1.3	168
178	Intracranial Tumors after Exposure to Ionizing Radiation during Infancy: A Pooled Analysis of Two Swedish Cohorts of 28,008 Infants with Skin Hemangioma. Radiation Research, 1998, 150, 357.	0.7	156
179	LONG-TERM FOLLOWUP OF A BLADDER CARCINOMA COHORT: ROUTINE FOLLOWUP UROGRAPHY IS NOT NECESSARY. Journal of Urology, 1998, 160, 45-48.	0.2	56
180	Intracranial Tumors after Radium Treatment for Skin Hemangioma during Infancy: A Cohort and Case-Control Study. Radiation Research, 1997, 148, 161.	0.7	15

#	Article	IF	CITATIONS
181	The Importance of the Depth of Invasion in Stage T1 Bladder Carcinoma: A Prospective Cohort Study. Journal of Urology, 1997, 157, 800-804.	0.2	132
182	Soft tissue sarcoma after treatment for breast cancer. Radiotherapy and Oncology, 1996, 38, 25-31.	0.3	74
183	Second-Line Endocrine Treatment of Advanced Breast Cancer—A Randomized Cross-Over Study of Medroxy-Progesterone Acetate and Aminoglutethimide. Acta Oncológica, 1996, 35, 75-75.	0.8	38
184	Physicians' attitudes toward clinical trials and their relationship to patient accrual in a nordic multicenter study on myeloma. Contemporary Clinical Trials, 1996, 17, 372-386.	2.0	30
185	Measurement of healthâ€related quality of life in multiple myeloma. British Journal of Haematology, 1996, 92, 604-613.	1.2	101
186	Clinical outcome of radioiodine treatment of hyperthyroidism: a follow-up study. Journal of Internal Medicine, 1996, 239, 165-171.	2.7	45
187	Prognostic factors for acute and late skin reactions in radiotheraphy patients. International Journal of Radiation Oncology Biology Physics, 1996, 36, 1065-1075.	0.4	274
188	Advanced Laryngeal Cancer T3-T4 in Sweden: A Retrospective Study 1986-1990. Survival and Locoregional Control Related to Treatment. Acta Oto-Laryngologica, 1996, 116, 906-912.	0.3	15
189	Cancer Incidence after Radiotherapy for Skin Haemangioma During Infancy. Acta Oncológica, 1995, 34, 735-740.	0.8	99
190	Patient accrual and quality of participation in a multicentre study on myeloma: a comparison between major and minor participating centres. British Journal of Haematology, 1995, 91, 109-115.	1.2	15
191	Cancer Morbidity in Rheumatoid Arthritis Patients Treated with Proresid <sup>R</sup> or Parenteral Gold. Scandinavian Journal of Rheumatology, 1995, 24, 79-84.	0.6	18
192	Renal function in newly diagnosed multiple myeloma — A demographic study of 1353 patients. European Journal of Haematology, 1994, 53, 207-212.	1.1	213
193	Initial versus deferred melphalanâ€prednisone therapy for asymptomatic multiple myeloma stage I — A randomized study. European Journal of Haematology, 1993, 50, 95-102.	1.1	188
194	Impact of active and passive exclusions on the results of a clinical trial in multiple myeloma. British Journal of Haematology, 1992, 80, 55-61.	1.2	49
195	Relationship Between Kerma and Treatment Volume in Intracavitary Radiation Therapy. Acta Oncológica, 1990, 29, 307-312.	0.8	3
196	Initial treatment in multiple myeloma: no advantage of multidrug chemotherapy over melphalan-prednisone. British Journal of Haematology, 1990, 74, 185-191.	1.2	47
197	Intracavitary Irradiation of Carcinoma of the Cervix Stage Ib and IIA: A clinical comparison between a remote high dose-rate afterloading system and a low dose-rate manual system. Acta Radiologica Oncology, 1985, 24, 139-144.	0.5	17
198	The effect of postoperative external radiotherapy on cervical carcinoma stage IB and IIA. Gynecologic Oncology, 1985, 22, 73-84.	0.6	22

#	Article	IF	CITATIONS
199	Incidence of pituitary adenomas in Western Sweden in 20012011. Endocrine Abstracts, 0, , .	0.0	ο
200	Longâ€ŧerm incidence of endometrial cancer after endometrial resection and ablation: A population based Swedish gynecologic cancer group ( <scp>SweGCG</scp> ) study. Acta Obstetricia Et Gynecologica Scandinavica, 0, , .	1.3	4